Get the Stockscreener App
0.2304
3.32%
0.0074
After Hours:
.23
-0.0004
-0.17%
AIM ImmunoTech Inc stock is traded at $0.2304, with a volume of 2.76M.
It is up +3.32% in the last 24 hours and down -7.99% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.223
Open:
$0.223
24h Volume:
2.76M
Relative Volume:
8.08
Market Cap:
$14.78M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
-0.576
EPS:
-0.4
Net Cash Flow:
$-21.85M
1W Performance:
-0.26%
1M Performance:
-7.99%
6M Performance:
-42.83%
1Y Performance:
-48.69%
1-Day Range:
$0.22
$0.26
1-Week Range:
$0.22
$0.2726
52-Week Range:
$0.2112
$0.62
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| AIM | 0.2304 | 14.78M | 202.00K | -28.96M | -21.85M | -0.40 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech Inc. (AMEX:AIM) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: AIM ImmunoTech reports progress on Ampligen, eyes partnerships - Investing.com India
AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strat - GuruFocus.com
AIM ImmunoTech Inc (AIM) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Aim Immunotech Reports Third Quarter Earnings - TipRanks
AIM ImmunoTech files to sell 9.31M shares of common stock for holders - TipRanks
AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
AIM Down on Q3 Results - Baystreet.ca
AIM ImmunoTech reports Q3 EPS (6c), consensus (9c) - TipRanks
Q3 2024 AIM ImmunoTech Inc Earnings Call Transcript - GuruFocus.com
AIM ImmunoTech Cuts Q3 Losses by 52%, Advances Pancreatic Cancer Treatment Program | AIM Stock News - StockTitan
AIM ImmunoTech Inc. (AIM) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires Additional Shares in AIM ImmunoT - GuruFocus.com
AIM ImmunoTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
AIM ImmunoTech stockholder Kellner Group issues letter on Board vote - TipRanks
AIM Immunotech's Largest Shareholder Fights Board After 99% Stock Collapse | AIM Stock News - StockTitan
Ted D Kellner Files Definitive Proxy Statement with Securities and Exchange Commission - Marketscreener.com
AIM ImmunoTech to Discuss Third Quarter 2024 Financial - GlobeNewswire
AIM ImmunoTech Sets Q3 2024 Earnings Call: Key Updates Expected Nov 15 | AIM Stock News - StockTitan
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders - messenger-inquirer
AIM ImmunoTech Files Definitive Proxy Statement with Securities and Exchange Commission - Marketscreener.com
AIM ImmunoTech Solicits Proxies from Shareholders - Marketscreener.com
Ted D. Kellner Files Preliminary Proxy Statement with Securities and Exchange Commission - Marketscreener.com
AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC - GlobeNewswire
Was there any good news for AIM ImmunoTech Inc (AIM) stock in the last session? - US Post News
AIM ImmunoTech Inc [AIM] Shares Fall -1.22 % on Thursday - Knox Daily
Ratios in Focus: Analyzing AIM ImmunoTech Inc (AIM)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis - The Manila Times
AIM ImmunoTech Inc’s latest rating changes from various analysts - Knox Daily
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment - Marketscreener.com
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering - The Manila Times
AIM ImmunoTech sees promising results in Ampligen combo for pancreatic cancer - MSN
AIM Stock Sees Decline of Approximately -18.54% in Last Five Days - Knox Daily
The Future of AIM ImmunoTech Inc: Analyzing AIM - The InvestChronicle
Deeper Dive: Understanding AIM ImmunoTech Inc (AIM) Through its Various Ratios - The Dwinnex
AIM ImmunoTech (NYSE:AIM) Shares Up 4.5% - Defense World
Hsbc Holdings PLC Increases Stock Holdings in Applied Industrial Technologies, Inc. (NYSE:AIT) - MarketBeat
AIM Under Threat? LSE Chief Raises Alarm - AskTraders
London Stock Exchange boss warns AIM is under threat of collapse - City A.M.
AIM future in doubt if business relief removed warns LSE chief - Proactive Investors Australia
Budget tax threat raises questions over AIM’s future - Financial News
Benjamin Edwards Inc. Has $318,000 Stake in Acuity Brands, Inc. (NYSE:AYI) - Defense World
AIM stock touches 52-week low at $0.25 amid market challenges - Investing.com Australia
Taking a look at what insiders are doing to gauge the AIM ImmunoTech Inc (AIM)’s direction - Knox Daily
Analyzing the Impact of Earnings Reports on AIM ImmunoTech Inc Inc. (AIM) Price Performance - The InvestChronicle
The future of AIM: how the small-cap market can survive - Interactive Investor
AIM ImmunoTech Inc (AIM) presents a great opportunity, but the stock is slightly undervalued - US Post News
Investor’s Delight: AIM ImmunoTech Inc (AIM) Closes Weak at 0.29, Down -2.45 - The Dwinnex
Clear Street LLC Takes Position in Aimfinity Investment Corp. I (NASDAQ:AIMBU) - Defense World
AIMAIM ImmunoTech Inc. Latest Stock News & Market Updates - StockTitan
AIM ImmunoTech Reports Positive Preliminary Data in Phase - GlobeNewswire
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):